Document 6426525
Transcription
Document 6426525
Guidelines for Empirical Antimicrobial Use in Adults UCSF Moffitt-Long & Mt. Zion Hospitals, San Francisco General Hospital, VA Medical Center This publication is designed to assist clinicians in the initial selection and monitoring of antimicrobial therapy for adult patients at UCSF Medical Center, San Francisco General Hospital, and the VA Medical Center. Recommendations represent the consensus of contributors and the Infectious Diseases Management Programs. These recommendations may differ from product prescribing information. Some of the policies contained in this document are hospital specific, and these are noted where applicable. www.ucsf.edu/idmp. Online version has updated information, full text references, infectious diseases library, comprehensive antibiograms, and additional guidelines. I. Contact Information San Francisco Department of Public Health: 554-2830 -reporting of communicable diseases (e.g. STDs, meningococcus) -reporting and referrals to tuberculosis clinic (206-8524) UCSF Infectious Diseases Program Contact Information Infectious Diseases Consult Service (24hr consult pager): 719-9628 -formal ID service consultation -recommendations for diagnosis and treatment -approval of restricted laboratory tests Infectious Diseases Pharmacy (24hr pager): 443-9421 -approval of restricted antimicrobials -recommendations for antimicrobial selection and dosing Microbiology Laboratory: 353-1268 -results of microbiology testing -for susceptibility inquiries please have culture accession # Inpatient Pharmacy: 353-1154 -information on dosing and availability of antimicrobials Infection Control: 353-4343 -recommendations for infection control and patient isolation -reporting of suspected outbreaks Needlestick Hotline (24hr pager): 719-3898 -reporting and management of bloodborne pathogen exposures 1 SFGH Infectious Diseases Program Contact Information Infectious Diseases Consult Service (24hr consult pager): 719-4737 -formal ID service consultation -recommendations for diagnosis and treatment -approval of restricted antibiotics (see section IV) Microbiology Laboratory: 206-8576 -results of microbiology testing Inpatient Pharmacy: 206-8460 -information on dosing and availability of antimicrobials Infection Control: 206-5466 or 206-8451 -recommendations for infection control and patient isolation -reporting of suspected outbreaks -assistance with reportable diseases Needlestick Hotline (24hrs): 469-4411 -reporting and management of bloodborne pathogen exposures 2 SF VA Medical Center Infectious Diseases Program Contact Information Infectious Diseases Consult Service (24hr consult pager): 207-3614 -formal ID service consultation -recommendations for diagnosis and treatment -approval of restricted antibiotics (evenings, weekends) Infectious Diseases Pharmacist (pager): 804-5982 -approval of restricted antimicrobials (weekdays) -recommendations for antimicrobial selection and dosing Microbiology Laboratory: 221-4810, ext. 2267 -results of microbiology testing Inpatient Pharmacy: 221-4810, ext. 2935 -information on dosing and availability of antimicrobials Infection Control: 221-4810, ext.2728 or ext. 3762 -recommendations for infection control and patient isolation -reporting of suspected outbreaks -assistance with reportable diseases Needlestick Hotline (24hrs): 469-4411 -reporting and management of bloodborne pathogen exposures 3 II. Guidelines for Initial Therapy a. Hospitalized Adults Bone and Joint Infections Diagnosis Common Pathogens BONE AND JOINT INFECTIONS S. aureus Septic Arthritis: Including Streptococci prosthetic joint infection N. gonorrhoeae Coagulase negative staph (prosthetic joint) Enterobacteriaceae (rarely) Drug(s) of First Choice1 Vancomycin2 + Ceftriaxone5 1 gm IV q24h Or Piperacillin/tazobactam (Zosyn®) 4.5g IV q8h Osteomyelitis: Hematogenous S. aureus Vancomycin2 With vascular insufficiency or Diabetes Mellitus (e.g. severe diabetic foot ulcer) S. aureus Enterobacteriaceae Anaerobes Vancomycin2 Plus Piperacillin/ tazobactam (Zosyn®) 4.5 g IV q8h Alternative Drug(s)1 Comments For severe PCN allergy3: Vancomycin2 + Ciprofloxacin 400mg IV q12h Or Levofloxacin 500mg IV q24h4,5 (If gram stain shows GNR’s) Gram stain recommended to guide therapy For severe PCN allergy3: Vancomycin2 If nafcillin susceptible S. aureus then cefazolin 2g IV q8h or nafcillin 2g IV q6h are the antibiotics of choice Narrow coverage to microbiologically confirmed pathogens. ID consultation recommended For severe PCN allergy3: Other organisms are possible, esp. with hardwareVancomycin2 microbiologic diagnosis and ID consultation recommended Plus Ciprofloxacin 400mg IV q12h Or Levofloxacin 500mg q24h4,5 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 4 Skin and Soft Tissue Infections Diagnosis Common Pathogens SKIN AND SOFT TISSUE INFECTIONS Cellulitis Group A streptococci Other beta-hemolytic streptococci S. aureus less common Drug(s) of First Choice1 Cefazolin 1 g IV q8h Or Nafcillin 1-2 g IV q6h Alternative Drug(s)1 Comments The advantage of cefazolin is less frequent dosing For severe PCN allergy3: Clindamycin5 600-900 mg IV q8h Or Vancomycin2 The advantage of nafcillin is more focused and directed spectrum Increasing rates of MRSA in the community may be a cause for failure to respond to initial therapy. Nosocomial cellulitis may be due to MRSA or Enterobacteriaceae. Abscess S. aureus Vancomycin2 Necrotizing fasciitis or suspected deep tissue extension Group A streptococci S. aureus Anaerobes Gram neg bacilli Vancomycin2 + Piperacillin/tazobactam (Zosyn®) 4.5g IV q8h + Clindamycin5 600 – 900mg IV q8h Vancomycin2 + Gentamicin2+ Clindamycin5 600-900mg IV q8h Or Vancomycin2 + Imipenem5 500mg IV q 6-8h or Meropenem5 0.5-1g IV q8h +Clindamycin5 600900mg IV q8h 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 5 Endocarditis Diagnosis ENDOCARDITIS Native Valve Prosthetic Valve Common Pathogens Drug(s) of First Choice1 Alternative Drug(s)1 S. aureus Streptococci Enterococcus Occasional gram negative rods HACEK < 5% Vancomycin2 +/- S. aureus Vancomycin2 Plus Rifampin 300 mg PO q8h Plus Gentamicin2 1mg/kg/dose IV q8hfor initial two weeks only Single daily dose of gentamicin is not recommended Coag. negative staphylococci Ceftriaxone 2 g IV q24h Comments ID consultation is strongly recommended regarding choice and duration of therapy For severe PCN allergy3: Vancomycin2 ± Ciprofloxacin 400mg IV q12h Narrow coverage to microbiologically confirmed pathogens ID consultation is strongly recommended regarding choice and duration of therapy 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 6 Gynecologic Infections Diagnosis Common Pathogens Drug(s) of First Choice1 Alternative Drug(s)1 Comments For severe PCN allergy3: Clindamycin5 600 - 900 mg IV q8h Plus Levofloxacin5 500mg IV q24h or Gentamicin 5 mg/kg2 as a single daily dose Clindamycin5 600 - 900 mg IV q8h For severe PCN allergy3: Levofloxacin5 500 mg IV/PO daily + Metronidazole 500 mg IV/PO Q8h If test for chlamydia is positive and not using levofloxaicn, add azithromycin5 or doxycycline. GYNECOLOGIC INFECTIONS Endometritis Bacteroides Prevotella bivia Group B & A streptococci Enterobacteriaceae M. hominis Piperacillin/ tazobactam (Zosyn®) 4.5 g IV q8h or Ampicillin/sulbactam5 (Unasyn®) 3g IV q6h Group B streptococcal infection Pelvic inflammatory disease Group B streptococci Ampicillin 2 g IV q6h Chlamydia trachomatis M. hominis Neiserria gonorrhoeae Enterobacteriaceae Anaerobes Ampicillin/sulbactam5 3g IV q6h (Unasyn®) or Piperacillin/tazobactam (Zosyn®) 4.5gm IV q6h Plus Doxycycline 100 mg IV/PO q12h Or Ceftriaxone5 1g IV q24h + Doxycycline 100mg PO/IV q12h +/Metronidazole 500 mg IV/PO q8h or Clindamycin5 600 - 900 mg IV q8h Plus Gentamicin2 5 mg/kg as a single daily dose Plus Doxycycline 100 mg IV/PO q12h 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 7 Head and Neck Infections Diagnosis Common Pathogens HEAD AND NECK INFECTIONS Group A streptococci Peritonsillar abscess, deep Anaerobes neck infections Drug(s) of First Choice1 Ampicillin/sulbactam5 (Unasyn®) 3g IV q6h or Alternative Drug(s)1 Comments Often polymicrobial For severe PCN allergy3: Clindamycin5 600 – 900 mg IV q8h Plus Ciprofloxacin 400mg IV q12h Or Levofloxacin 500mg IV q24h5 Metronidazole 500 mg IV/PO q8h Plus Ceftriaxone5 1g IV q24h or Cefuroxime 750 mg IV q8h 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 8 Intra-abdominal Infections Diagnosis Common Pathogens INTRA-ABDOMINAL INFECTIONS SBP (Spontaneous E. coli Bacterial Peritonitis) Klebsiella Strep. spp. Drug(s) of First Choice1 Ceftriaxone5 1g IV q24h Alternative Drug(s)1 Comments Gram stain recommended For severe PCN allergy3: Vancomycin2 or Clindamycin 600-900mg IV q8h Plus Secondary Peritonitis Moderate to severe, intraabdominal abscess Severe, major peritoneal soilage, large or multiple abscesses, patient hemodynamically unstable E. coli Klebsiella B. fragilis Enterococcus E. coli Klebsiella B. fragilis Piperacillin/ tazobactam (Zosyn®) 4.5g q 8h Piperacillin/ tazobactam (Zosyn®) 4.5 g IV q8h Plus Gentamicin2 Gentamicin2 or Aztreonam5 2g IV q8h For severe PCN allergy3: Metronidazole 500 mg IV/PO q8h Plus Aztreonam5 2g IV q8h or Gentamicin2 Imipenem5 0.5 g IV q6h or Meropenem5 1 g IV q8h ID consultation is recommended For severe PCN allergy3: Vancomycin2 Plus Metronidazole 500 mg IV q8h Plus Gentamicin2 or Aztreonam5 2g IV q8h E. coli For severe PCN allergy3: Necrotizing pancreatitis ID consultation is recommended. Piperacillin/ Klebsiella, Enterobacter Metronidazole 500 mg IV tazobactam (Zosyn®) B. fragilis q8h Antibiotics in this setting are for prevention, not treatment, 4.5 g IV q8h Enterococcus of infection and should be used for the shortest possible Plus S.aureus duration. Ciprofloxacin 400mg IV q12h Or Levofloxacin 500mg IV q24h4 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC Enterococcus 9 Line-Related Infections Diagnosis Common Pathogens Drug(s) of First Choice1 Alternative Drug(s)1 Comments LINE-RELATED INFECTIONS Vancomycin2 Line-related bacteremia Staph. epidermidis Vancomycin2 Remove the offending intravascular device immediately, if possible. (+ peripheral blood culture) Staph. aureus ± ± Yeast Ciprofloxacin 400mg IV Piperacillin/tazobactam Enterococci q12h (Zosyn®) Occasional gram negative Or 4.5g IV q8h rods Levofloxacin 500mg q24h5 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 10 Meningitis Diagnosis MENINGITIS Meningitis Common Pathogens Strep. pneumoniae Neisseria meningitidis Listeria (especially in immuno-compromised, elderly patients, and alcoholics) Drug(s) of First Choice1 Ceftriaxone5 2 g IV q12h Plus Vancomycin2 Alternative Drug(s)1 For severe PCN allergy3: Vancomycin2 + Aztreonam5 2g IV q8h ± Trimethoprim/Sulfametho xazole (if Listeria) 15 mg/kg/day (in divided doses) Comments ID consultation recommended Therapy should be guided by Gram stain If bacterial meningitis suspected, dexamethasone 10 mg PO/IV q6h x 4 days given before or with initial dose of If Listeria suspected add: antibiotics Trimethoprim/ Sulfamethoxazole (TMP/SMX) 15 mg/kg/day (in divided doses) Or Ampicillin 2g IV q4h Cefepime 2g IV q8h5 Aztreonam5 2 g IV q8h Open head trauma or surgery Staph. aureus ID consultation recommended Gram negative rods Plus Plus 2 2 Vancomycin Vancomycin 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 11 Pneumonia, Community-Acquired Diagnosis Common Drug(s) of First Choice1 Pathogens PNEUMONIA, COMMUNITY ACQUIRED BACTERIAL Immunocompetent patient – Strep. pneumoniae No Recent antibiotic Medical Ward Mycoplasma pneumoniae therapy:* Chlamydia pneumoniae Ceftriaxone5 1g IV q24h H. influenzae or Cefuroxime 1.5 g IV Legionella pneumophilia q8h (SFVAMC) Klebsiella pneumoniae Plus (alcoholics) Doxycycline 100 mg PO/IV q12h Anaerobic lung abscess Anaerobes Gram-positive oral flora Clindamycin5 600 – 900 mg IV q8h Immunocompetent patient – ICU no Pseudomonas coverage Strep. pneumoniae Mycoplasma pneumoniae Chlamydia pneumoniae H. influenzae Legionella pneumophilia Klebsiella pneumoniae (alcoholics) Ceftriaxone5 1g IV q24h Plus Azithromycin 500 mg IV q24h Alternative Drug(s)1 For severe PCN allergy3: Antipneumococcal fluoroquinolone5: Levofloxacin 500mg IV q24h or Moxifloxacin 400mg IV q24h or Gatifloxacin 400mg IV q24h Comments Fluoroquinolones are not routinely recommended as firstline therapy because of concerns about resistance ID consultation is recommended if ICU admission or high level PCN-resistant pneumococci documented *If patient has had recent antibiotic therapy, antibiotics from a different class should be selected i.e. recent use of a FQ should dictate selection of a non-FQ regimen, and vice versa. ID consultation is recommended For severe PCN allergy3: Antipneumococcal fluoroquinolone5: Levofloxacin 500mg IV q24h or Moxifloxacin 400mg IV q24h or Gatifloxacin 400mg IV q24h ± Clindamycin5 600-900mg IV q8h Aztreonam5 2g IV q8h ID consultation is recommended. Piperacillin/ Plus Tazobactam (Zosyn®) 5 Levofloxacin 750 mg IV Note antipseudomonal dosing 4.5g IV q6h q24h Plus Ciprofloxacin5 400 mg IV q8h 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC Immunocompetent patient – ICU Pseudomonas coverage desired As above and Pseudomonas 12 Pneumonia, Nosocomial Diagnosis Common Pathogens PNEUMONIA, NOSOCOMIAL BACTERIAL E. coli Ventilator-associated Enterobacter pneumonia [VAP] P. aeruginosa Klebsiella Staph. aureus Drug(s) of First Choice1 Alternative Drug(s)1 If NO previous antibiotic therapy: Vancomycin2 Plus either Piperacillin/ tazobactam (Zosyn®) 4.5 g IV q8h or Cefepime5 2g IV Q8h If NO previous antibiotic therapy: For severe PCN allergy3: Vancomycin2 Plus Ciprofloxacin 400mg IV q8h or Levofloxacin 750mg IV q24h5 If previous antibiotic therapy: Vancomycin2 Plus Imipenem5 500mg IV q6-8h or Meropenem5 0.5-1g IV q8h If previous antibiotic therapy: Vancomycin2 Plus Ciprofloxacin5 400mg IV q8h Plus Aztreonam5 2g IV q8h Comments Mini-BAL recommended Legionella empirically covered by fluoroquinolone5, doxycycline, or macrolide; ID consultation recommended for confirmed disease 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 13 Septic Shock Diagnosis SEPTIC SHOCK Septic shock – community acquired Common Pathogens Enterobacteriaceae S. aureus Streptococci Septic shock – healthcareassociated and/or previous antibiotic therapy Drug(s) of First Choice1 Alternative Drug(s)1 Vancomycin2 Plus Piperacillin/ tazobactam (Zosyn®) 4.5 g IV q8h For severe PCN allergy3: Vancomycin2 + Metronidazole 500mg IV/PO q8h + Gentamicin2 Vancomycin2 + Imipenem5 500mg IV q6-8h or Meropenem5 0.5-1g IV q8h For severe PCN allergy3: Vancomycin2 + Metronidazole 500mg IV q8h + Gentamicin2 or Ciprofloxacin 400mg IV q8h5 Comments For hospital-acquired infections ID consultation is recommended 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 14 Tuberculosis Diagnosis TUBERCULOSIS Suspected tuberculosis Common Pathogens Drug(s) of First Choice1 Alternative Drug(s)1 Comments ID consultation is recommended Isoniazid 300 mg PO daily Plus Notify the SF Department of Public Health or call TB Rifampin 600 mg PO Clinic @ SFGH (206-8524) daily Plus Pyrazinamide 25 mg/kg/day PO daily Plus Ethambutol 20 mg/kg/day PO daily Plus Pyridoxine (Vitamin B6) 50 mg PO daily 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC Mycobacterium tuberculosis 15 Urinary Tract Infections Diagnosis Common Pathogens URINARY TRACT INFECTIONS Uncomplicated cystitis or Enterobacteriaceae (e.g. pyelonephritis E. coli, Proteus) Staph. saprophyticus Drug(s) of First Choice1 Ceftriaxone5 1g IV Q24H or Cefazolin 1g IV q8h Pyelonephritis with urosepsis Enterobacteriaceae (e.g. E. coli, Proteus) Staph. saprophyticus Piperacillin/ tazobactam (Zosyn®) 4.5 g IV q8h Catheter-associated candiduria Candida species No treatment required Alternative Drug(s)1 Comments Ciprofloxacin 400mg IV q12h or Levofloxacin 500mg IV q24h4,5 Or Gentamicin2 For severe PCN allergy3: Vancomycin2 Plus Gentamicin2 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 16 b. Outpatients Bites Diagnosis Common Pathogens BITES Consider evaluation for tetanus prophylaxis for all bites. Dog and Cat Streptococci Pasteurella spp.* Staphylococci Anaerobes Drug(s) of First Choice1 Amoxicillin/ clavulanate 875mg/125mg PO BID Prophylaxis – x 5 days Treatment – x 10 days Alternative Drug(s)1 Comments Only 5% of dog bites become infected, whereas 30-50% of cat bites become infected. For PCN allergic patients3: Clindamycin 300mg PO TID + Ciprofloxacin 500mg PO q12h or Levofloxacin 500mg PO q24h5 Prophylaxis in high risk patients or in high risk bite only High risk patient = post splenectomy, immunocompromised (eg., cirrhosis) Prophylaxis – x 5 days Treatment – x 10 days High risk bite = hand or foot Treatment – if infection present, treatment should be guided by cultures; careful follow-up every 2-3 days recommended. *P.multocida is resistant to cephalexin & clindamycin; many strains are resistant to erythromycin but sensitive to fluoroquinolones, doxycycline and penicillin. If culture positive for P.multocida as sole organism, can switch to PCN VK PO Human Viridans streptococci Eikenella* Oral anaerobes Amoxicillin/ clavulanate 875mg/125mg PO BID Prophylaxis – x 5 days Treatment – x 10 days Cleaning, irrigation and debridement important. For clenched fist injuries,x-rays should be obtained; infected patients are usually admitted For PCN allergic patients2: Clindamycin 300 mg PO TID Plus Ciprofloxacin 500mg PO q12h or Levofloxacin 500mg PO q24h4, 5 or Trimethoprim/ sulfamethoxazole DS One Tab PO BID *Eikenella resistant to clindamycin, metronidazole, 1st gen cephalosporins and erythromycin; susceptible to fluoroquinolones5, clarithromycin, doxycycline, and TMP/SMX. Careful follow-up every 2-3 days Prophylaxis – x 5 days Treatment – x 10 days 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 17 Bronchitis Diagnosis BRONCHITIS Acute Bronchitis Common Pathogens Viral Drug(s) of First Choice1 No drug therapy required Alternative Drug(s)1 No drug therapy required Comments Antibiotics are NOT useful in acute bronchitis. Purulent sputum alone is not an indication for antibiotics. Acute bacterial exacerbation of chronic bronchitis (COPD) S. pneumoniae H. influenzae Moraxella catarrhalis Doxycycline 100 mg PO BID x 10 days Azithromycin5 500 mg PO daily x 1 day; then 250 mg PO daily x 4 days. 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 18 Skin and Soft Tissue Infections Diagnosis Common Pathogens SKIN AND SOFT TISSUE INFECTIONS Cellulitis Group A streptococci (90-95%) Staph. aureus (5-10%) Drug(s) of First Choice1 Alternative Drug(s)1 Dicloxacillin 500 mg PO QID x 10 days, then reassess. Or Cephalexin 500 mg PO QID x 10 days, then reassess. If mild PCN allergy3: Cephalexin 500 mg PO QID x 10 days Comments If severe PCN allergic3: Clindamycin 300 mg PO TID x 10 days. Or Abscess S. aureus Clindamycin or doxycycline if MRSA is a specific concern I&D alone sufficient in most cases See pg 43 for more details 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 19 Foot Ulcer (Diabetic) Diagnosis Common Pathogens FOOT ULCER (DIABETIC) S. aureus Localized cellulitis without Strep. spp. systemic signs or symptoms, no osteomyelitis Drug(s) of First Choice1 Cephalexin 500 mg PO QID for 10-14 days Or Dicloxacillin 500 mg PO QID x 10-14 days Alternative Drug(s)1 For PCN allergic patients3: Clindamycin 300 mg PO TID for 10-14 days Comments Consider osteomyelitis especially if there is a failure to respond to therapy. While infections may be polymicrobial, they respond to treatment of staph and strep. Increasing rates of MRSA in the community may be a cause for failure to respond to initial therapy. Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 1 20 Diverticulitis Diagnosis DIVERTICULITIS No signs of bowel perforation. If bowel perforation, see Peritonitis on Inpatient Antibiotic Guidelines Common Pathogens Enterobacteriaceae Bacteroides fragilis Enterococcus Drug(s) of First Choice1 Amoxicillin/ clavulanate 875mg/125mg PO BID Or Fluoroquinolone4 Plus Metronidazole 500mg PO q8h Duration of treatment should be until patient is afebrile for 3-5 days Alternative Drug(s)1 For PCN allergic patients3: Ciprofloxacin 500mg PO q12h Or Levofloxacin 500mg PO q24h Plus Metronidazole 500mg PO q8h Comments Surgical evaluation and follow up is advised. Duration of treatment should be until patient is afebrile for 3-5 days 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 21 Gastroenteritis Diagnosis GASTROENTERITIS Clinical Presentation Dysenteric Diarrhea Frequent, sometimes bloody, small-volume diarrhea associated with abdominal pain and cramping. Patient may be febrile and toxic. Common Pathogens Presumed bacterial pathogen Drug(s) of First Choice1 Ciprofloxacin 500 mg PO BID x 3-5 days. Comments General Comments Empiric therapy is generally indicated if patient is toxic appearing, elderly or immunocompromised. If empiric therapy is given, obtain culture and give fluoroquinolone x 3 days while awaiting cultures. Shigella Salmonella Campylobacter Antimotility drugs improve symptoms and can be used if patient is not toxic. Antimotility drugs should not be used in C.difficile. Yersinia E. coli 0157:H7 Strict handwashing is mandatory in all food preparation. Antimicrobial treatment may worsen outcomes in patients with E. coli 0157:H7 C. difficile - Metronidazole 500 mg PO TID x 10-14 days. Nondysenteric Diarrhea Viruses Large volume, nonbloody, watery diarrhea. Patient may have nausea, vomiting, and abdominal cramping but fever often absent Giardia Traveler’s diarrhea Empiric treatment while abroad Enterotoxigenic E. coli Enterotoxin-producing bacteria Toxigenic E. coli Salmonella Shigella Campylobacter General Care: Observation Oral rehydration Antimotility agents Giardia – especially if patient describes recent history of travel and/or ingestion of unfiltered water (e.g., camping), consider – Metronidazole 250 mg PO TID x 5 days. Ciprofloxacin 500 mg PO BID x 3-5 days (Pregnancy: Azithromycin5 1gm x 1 or 500 mg daily x 3days) Plus Loperamide 4 mg PO x1; then 2 mg after each loose stool, MAX 16 mg/day. E. histolytica - Metronidazole 750 mg PO TID x 5-10 days then Iodoquinol 650 mg PO TID x 21 days or Paromomycin5 500 mg TID x 7 days Generally, empiric therapy and stool cultures are not indicated. Most disease is self-limiting and can be treated with antimotility agents. If patient fails to improve, cultures (-), and symptoms persist, consider stool for O & P Check C. difficile toxin if recent history of antibiotic use or hospitalization. Mild, self-limited cases can be treated with fluid and electrolyte repletion and bismuth subsalicylate. Prophylaxis generally not recommended. Amebiasis 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 22 Herpes Simplex Virus Infections Diagnosis Common Pathogens HERPES SIMPLEX VIRUS (HSV) INFECTIONS GENITAL HERPES HSV 2 = 70-90% Acute HSV 1 = 10-30% Recurrent Episodes Suppression for Frequent Recurrence HSV 2 = 70-90% HSV 1 = 10-30% Drug(s) of First Choice1 Alternative Drug(s)1 Acyclovir 400 mg PO TID x 7-10 days Valacyclovir5 1 g PO BID x 7-10 days Acyclovir 400 mg PO TID x 5 days or Acyclovir 800 mg PO BID x 5 days Valacyclovir5 500 mg 1000 mg PO daily x 5 days Acyclovir 400 mg PO BID Valacyclovir5 500 – 1000mg PO daily Comments In HIV patients with documented acyclovir resistance, use foscarnet. Consider suppressive therapy for patients experiencing greater than 3-4 episodes in 12 months. Valacyclovir5 500 mg daily may be less effective in patients who have > 10 episodes/year FACIAL/ORAL HERPES Recurrent episodes in immunocompetent patients HSV 1 No therapy required ( Valacyclovir5 2g PO Q12h x 1 day Therapy of recurrent disease is of marginal benefit and most do not treat. HSV 2 Short-term prophylactic therapy with acyclovir may be desirable in some patients who anticipate intense exposure to UV light (e.g., skiers, or in those who work outdoors), although the clinical effect may vary. 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC Acyclovir 400 mg PO TID x 5 days 23 Herpes Zoster Infections Diagnosis Common Pathogens HERPES ZOSTER INFECTIONS Varicella-Zoster Virus Immuno-competent (Shingles/ Zoster) Drug(s) of First Choice1 Acyclovir 800 mg PO 5x/day x 7-10 days Or Immuno-compromised (Lymphoma, HIV infection, etc) and not severe (one dermatome) Primary Infection in Adults (Chicken Pox) Valacyclovir5 1 g PO TID x 7 days Varicella-Zoster Virus Alternative Drug(s)1 Acyclovir 800 mg PO 5x/day x 5 days Or Valacyclovir5 1 g PO TID x 5 days Famciclovir 500 mg PO TID x 7 days (more expensive) Comments Treatment effective only if initiated within 48-72 hours of onset of lesions. May shorten duration of illness in immunocompetent patients. In patients > 65 years old administration of concomitant corticosteroids may improve quality of life. Initiate therapy within 24 hours of onset of rash. Vaccination of non-immune close contacts recommended. Acyclovir treatment may also be effective for prophylaxis of at-risk individuals. 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 24 Mastitis Diagnosis MASTITIS Postpartum Common Pathogens Staph. aureus Drug(s) of First Choice1 Alternative Drug(s)1 Dicloxacillin 500 mg PO QID x 10 days Or Cephalexin 500 mg PO QID x 10 days For mild PCN allergy3: Cephalexin 500 mg PO QID x 10 days Comments If no abscess, increased frequency of nursing may hasten response. If abscess, I & D required; discontinue nursing. For severe PCN allergy3: Clindamycin 300 mg PO TID x 10 days Increasing rates of MRSA in the community may be a cause for failure to respond to initial therapy. Doxycycline is active against 95% of MRSA but should not be used if breastfeeding. TMP-SMX and clindamycin generally are active. 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 25 Otitis media Diagnosis OTITIS MEDIA Acute with effusion Common Pathogens Drug(s) of First Choice1 Alternative Drug(s)1 Comments Strep. pneumoniae (25-50%) H. influenzae (15-30%) M. catarrhalis (3-20%) Group A Strep. (2%) Amoxicillin 500 mg PO TID x 5-7 days For severe penicillin allergy3: Azithromycin5 500 mg PO QD x 1 day; then 250 mg PO QD x 4 days. Or Amoxicillin/clavulanic acid not indicated as initial therapy of acute otitis. Or Doxycycline 100 mg PO BID for 5-7 days For recurrent prolonged otitis consider ENT referral. High dose amoxicillin 1 g PO TID should be used over low dose (500 mg PO TID) in the treatment of patients at risk for drug resistant S. pneumoniae. 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 26 Pharyngitis/Tonsilitis Diagnosis Common Pathogens PHARYNGITIS/TONSILLITIS Viral (EBV, rhinovirus, Pharyngitis coronavirus, adenovirus etc) Group A Streptococcus (5-20%) Drug(s) of First Choice1 Penicillin VK 500 mg PO QID x 10 days Alternative Drug(s)1 For PCN allergic patients3: Clindamycin 300 mg PO TID x 7-10 days Comments Most pharyngitis is viral thus antibiotics should not be used. Treatment with PCN prevents rheumatic fever. Treat documented Group A streptococcal infection confirmed by rapid strep. antigen test or culture or if 3 out 4 clinical criteria present. Clinical Criteria: history of fever, tender anterior cervical adenopathy, absence of cough, tonsillar exudates. Penicillin resistance has not been observed. Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 1 27 Pneumonia, Community-acquired Diagnosis Common Pathogens PNEUMONIA, COMMUNITY ACQUIRED (CAP) S. pneumoniae Adult M. pneumoniae C. pneumoniae Respiratory viruses Legionella spp. C. psittaci H. influenzae (if patient has co-morbidity) Anaerobic lung infection Regimens Comments No recent antibiotic therapy: Doxycycline 100 mg PO BID x 7-10 days Or Azithromycin5 500 mg PO daily x 1 day; then 250 mg PO daily x 4 days Previous antibiotic therapy within last 3 month should be elicited from patient. A course of antibiotics is a risk factor for drug resistance. Recent use of a fluoroquinolone should dictate selection of a non-fluoroquinolone regimen, and vice versa. Recent antibiotic therapy or patients with comorbidities: Antipneumococcal fluoroquinolone5 : Levofloxacin 500mg PO q24h x 7-10days Or Gatifloxacin 400mg PO q24h x 7-10 days Or Moxifloxacin 400mg po q24h x 7-10 days Or Azithromycin5 500mg PO daily x 1; then 250mg PO daily x 4 days or Doxycycline 100mg PO q12h x 7-10 days Plus Amoxicillin (High-dose) 1g PO TID Amoxicillin/clavulanate 875/125mg PO q12h Or Clindamycin 300mg po TID Careful follow-up highly recommended. 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 28 Prostatitis Diagnosis PROSTATITIS Acute Chronic Common Pathogens Drug(s) of First Choice1 Enterobacteriaceae (E. coli) Enterococci Ciprofloxacin 500 mg PO BID X 21 days* Or Levofloxacin5 500 mg PO daily x 21 days* Or Cephalexin 500 mg PO qid x 21 days Ciprofloxacin x 2-3 months* Or Levofloxacin5 x 2-3 months* Or Trimethoprim/ Sulfamethoxazole1 DS tablet bid Or Doxycycline 100 mg PO bid Enterobacteriaceae (E. coli) Enterococci Alternative Drug(s)1 Comments *Cultures should be obtained and definitive therapy for 21 days should be based on sensitivities. Antibiotic penetration in the acute inflammatory state is adequate for the use of most antibiotics. *Cultures should be obtained and definitive therapy should be based on sensitivities. Few drugs penetrate non-inflamed prostate. Fluoroquinolone, trimethoprim/sulfamethoxazole and doxycycline adequately penetrate in non-inflamed state. Use TMP/SMX if organism is susceptible. Consider sexually transmitted disease treatment (Gonococcus or C. trachomatis) for appropriate patient populations. Consider sexually transmitted disease treatment (Gonococcus or C. trachomatis) for appropriate patient populations. Consider urologic evaluation. 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 29 Pyelonephritis Diagnosis Common Pathogens Drug(s) of First Choice1 Enterobacteriaceae (E. coli) Enterococci Fluoroquinolone4,5 x 714 days Alternative Drug(s)1 Comments PYELONEPHRITIS Or Cephalexin 500 mg PO qid Based on sensitivity. Trimethoprimsulfamethoxazole is preferred if organism is susceptible. For patients not tolerating oral therapy, may initiate therapy with single dose parenteral ceftriaxone or aminoglycoside while awaiting culture. 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 30 Sexually Transmitted Diseases (STDs) Diagnosis Common Pathogens SEXUALLY TRANSMITTED DISEASES (STDs) T. pallidum Syphilis Early Latent Gonorrhea Drug(s) of First Choice1 Alternative Drug(s)1 Comments Benzathine penicillin G 2.4 MU IM X 1 dose (early) Doxycycline 100 mg PO BID X 2 weeks Sexual partners must be treated. Considering high frequency of Neisseria coinfection with Chamydia, concomitant therapy with azithromycin, doxycycline, or erythromycin must be administered. All cases of syphilis and Gonococcus must be reported to the San Francisco Public Health Department at 554-2830. Benzathine penicillin G 2.4 MU IM Q week X 3 doses (latent) N. gonorrhoeae Cefpodoxime 400 mg PO X 1 dose Or Ceftriaxone 125 mg IM X 1 dose Each of the above courses should be followed by azithromycin 1 g PO X 1 or doxycycline 100 mg BID PO X 7 days or erythromycin 500 mg QID PO X 7 days Chlamydia cervicitis Chlamydia trachomatis PID (Pelvic Inflammatory Disease) N.gonorrhoeae C.trachomatis anaerobes Gram-negative facultative bacteria streptococci Sexual partners must be treated. Pharyngeal Gonococcus must be treated with Ceftriaxone. Fluoroquinolones should not be used for infections acquired in CA, Asia, and the Pacific, including Hawaii, due to increasing resistance and treatment failures. Azithromycin 1g PO once Levofloxacin5 500 mg PO daily x 14 days ± Metronidazole 500 mg PO BID x 14 days Doxycycline 100 mg PO q12h x 7 days Follow-up examination should be performed within 72 Ceftriaxone 250 mg IM hours when PID is treated with these regimens in a single dose Plus Fluoroquinolones should not be used for N.gonorrhoeae Doxycycline 100 mg PO infections acquired in CA, Asia, and the Pacific, including BID x 14 days Hawaii, due to increasing resistance and treatment failures. ± Metronidazole 500 mg PO BID x 14 days 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 31 Sinusitis Diagnosis Common Pathogens Drug(s) of First Choice1 Alternative Drug(s)1 Comments Viruses Strep. pneumoniae H. influenzae M. catarrhalis Amoxicillin 500 mg PO q8h x 5-7 days For severe PCN allergy3: Doxycycline 100 mg PO BID x 5-7 days Or Azithromycin 500mg PO daily x 3 days Majority of cases are viral. Viruses Amoxicillin/ clavulanate 875mg/125mg PO BID x 10-14 days For PCN allergic patients3: Ciprofloxacin 500mg PO q12h or Levofloxacin 500mg PO q24h 5 x 10-14 days ± Clindamycin 300mg PO Consider otolaryngology consult to rule out anatomic abnormality. SINUSITIS, ACUTE Consider treatment only in presence of fever, purulence or bloody discharge following an upper respiratory infection if symptoms persist for 7-10 days suggesting bacterial etiology. SINUSITIS, CHRONIC Strep. pneumoniae H. influenzae M. catarrhalis or If acute exacerbation, treat as acute sinusitis. HIV positive patients may need a 2-3 week course. *DRSP=drug-resistant Streptococcus pneumoniae Amoxicillin/ clavulanate CR 2 g BID x 10-14 days if DRSP* suspected 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC Anaerobes Staph. aureus Enterobacteriacae 32 Tuberculosis Diagnosis TUBERCULOSIS Treatment Latent TB Common Pathogens Mycobacterium tuberculosis Drug(s) of First Choice1 Isoniazid (INH) 300 mg PO daily x 6 months Plus Rifampin 600 mg PO daily x 6 months Plus Pyrazinamide (PZA) 25 mg/kg PO daily x 2 months Plus Ethambutol 15 mg/kg PO daily until Isoniazid or Rifampin sensitivity established Plus Pyridoxine (Vitamin B-6) 50 mg PO daily for 6 months Isoniazid 300 mg po daily x 9 months Comments All cases of tuberculosis must be reported. Call the SF Department of Public Health at 206-8524. Smear positive cases should receive directly observed therapy. Other cases often receive directly observed therapy at the discretion of the Tuberculosis Control Unit. Obtain baseline LFT’s on all patients. Additional LFT’s advised if liver disease present. Perform a monthly symptom review if LFTs are normal Rifampin 600 mg PO daily x 4 months 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 33 Urinary Tract Infection (UTI) Diagnosis Common Pathogens URINARY TRACT INFECTION (UTI) Enterobacteriaceae (E. coli) Uncomplicated Enterococci Cystitis, Women Staph. saprophyticus (Coagulase negative staphylococcus) (4%) Women Recurrent Cystitis (3 or more episodes/year) Enterobacteriaceae (E. coli) Staph. saprophyticus (Coagulase negative staphylococcus) (4%) Enterococci Drug(s) of First Choice1 Alternative Drug(s)1 30% of cultured E. coli isolates are resistant to trimethoprim/ sulfamethoxazole Trimethoprim/Sulfame thoxazole 1 DS BID x 3 days (if no previous antibiotic therapy) Or Nitrofurantoin 50-100 mg QID x 7 days (women) – contraindicated in renal failure Or Cephalexin 500 mg PO qid x 7 days Or Ciprofloxacin 500mg PO q12h or Levofloxacin 500mg PO q24h x 3 days (try to minimize overuse of this class) Prophylaxis: Either self administration if symptoms occur or prophylactic post-coital antibiotics Comments Antibiotic choice should be based on susceptibility results of previous culture Post menopausal :topical estrogen Men Consider urologic evaluation Recurrent 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC 34 Vaginitis Diagnosis VAGINITIS Fungal Protozoan Common Pathogens Candida albicans Trichomonas vaginalis Drug(s) of First Choice1 Fluconazole5 150 mg PO X 1 dose Metronidazole 2 g PO X 1 dose Or Metronidazole 500 mg BID PO X 7 days Metronidazole 2 g PO X 1 dose Or Metronidazole 500 mg BID PO X 7 days Alternative Drug(s)1 Butoconazole5 (2% cream) X 3 days Or Terconazole5 (0.8% cream or 80 mg suppository) X 3 days Or Miconazole5 (200 mg suppository) once daily X 3 days Tinidazole5 2 g PO x 1 Comments Single dose topical therapies are available but are less effective. Seven day courses of therapy are not superior to 3 day regimens In treatment failures to metronidazole, retreat with metronidazole 500 mg PO BID x 7 days. Tinidazole 2 g PO x 1 may also be effective for metronidazole-resistant trichomoniasis. A single 2 g dose of metronidazole is slightly less Clindamycin vaginal efficacious compared to the 7 day course of therapy. cream QD X 7 days However, single dose therapy may be preferable due to Or compliance. Metronidazole vaginal gel BID X 7 days Or Clindamycin 300 mg BID PO X 7 days 1 Doses provided in this table are for patients with normal renal and hepatic function. Consult Antimicrobial Dosing Guidelines (pg. 36-41) for dosing adjustment required in renal dysfunction. 2 For dosing of vancomycin and aminoglycosides, refer to Antimicrobial Dosing Guidelines (pg. 36-41) and sections on vancomycin monitoring (pg. 33) and aminoglycoside dosing and monitoring (pg. 34-35) 3 Severe PCN allergy defined as anaphylaxis, bronchospasm, and hives. Mild PCN allergy defined as non- IgE mediated (i.e maculopapular rash or drug fever). 4 Fluoroquinolone=Ciprofloxacin or Levofloxacin unless otherwise noted 5 ID approval needed at SFVAMC Bacterial Gardnerella, other anaerobes 35 III. a. Antibiotic Dosing Guidelines Vancomycin Monitoring Vancomycin dosing is based on the patient’s actual body weight and requires adjustment in renal dysfunction. Monitoring of serum levels should not be performed routinely on all patients receiving vancomycin. However, a vancomycin trough may be needed in some instances prior to transfer (e.g. to Laguna Honda Hospital for prolonged antibiotic therapy). Consult I.D. or I.D. pharmacy with questions. Vancomycin levels are recommended for: ·Patients with rapidly changing renal function ·Patients on intermittent or continuous hemodialysis ·Patients with severely altered volumes of distribution (e.g. morbid obesity, significant edema, burns) ·Initial and definitive therapy of suspected CNS infection, endocarditis, or osteomyelitis ·Patients with persistent bacteremia while on treatment or infections associated with an indwelling foreign body (other than intravenous catheters) ·Patients >60 yo Trough levels only should be obtained. Vancomycin peaks have no clinical significance. Trough levels should be obtained within 30 minutes before the 3rd or 4th dose of a new regimen. Doses should be adjusted to obtain a trough level of 10-15mcg/ml for most indications. For management of central nervous system infections, endocarditis, ventilator-associated pneumonia or osteomyelitis, or in patients not responding to initial treatment, trough levels of 10-20 mcg/ml are suggested. 36 b. Aminoglycoside Dosing and Monitoring Aminoglycoside antibiotics have limited tissue distribution and are renally cleared. Dosing is based on a patient’s ideal or adjusted body weight and renal function. Careful selection of empiric dosing regimens and serum level monitoring when warranted are needed to ensure safety and efficacy of these drugs. Patients anticipated to receive aminoglycosides for >2 weeks should be considered for audiometry. There are several approaches to dosing aminoglycosides (does not cover special populations such as cystic fibrosis, pregnancy, or post-partum): Ideal Body Weight: Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet. Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet. Adjusted Body Weight: ABW = IBW + 0.4 (actual weight - IBW) Consider using ABW if actual weight is >30% of calculated IBW. CrCl (mL/min) = (140-Age) x Wt (kg) 72 x SCr (mg/dl) [for females multiply by 0.85] MULTIPLE-DAILY DOSING (“TRADITIONAL”) -This approach should be used for the treatment of Gram-negative infections when “once-daily” dosing is not appropriate. Inclusion criteria: -Patients with suspected or documented Gram-negative infections not eligible for “once-daily” dosing. -Patients with documented serious Gram-negative infections (e.g. Pseudomonas) receiving aminoglycosides in combination with a beta-lactam agent. Exclusion criteria: -Patients using aminoglycosides for synergistic activity against Gram-positive organisms (see below). Dosing: CrCl Dose (gentamicin, tobramycin) >60 ml/min 1.5-1.7 mg/kg/dose IV q8h 40-60 ml/min 1.2 - 1.5 mg/kg/dose IV q12h 20-40 ml/min 1.2-1.5 mg/kg/dose IV q12-24h <20 ml/min 2 mg/kg loading dose ·A 2mg/kg loading dose may be administered in patients with severe infections. ·Contact ID pharmacy for maintenance doses for patients with CrCl <20 ml/min. Monitoring: ·Patients anticipated to receive aminoglycosides for >7 days should have levels monitored. ·For patients who require monitoring, draw peak and trough level. ·Peak levels should be drawn 30 minutes after the end of the infusion. Trough levels should be drawn immediately before the next dose. Levels should be drawn around the 3rd or 4th dose to allow the drug to reach steady-state. Desired level (gentamicin, tobramycin) Trough <2 mcg/ml (<1 mcg/ml optimal) Peak 5-8 mcg/ml 37 HIGH-DOSE, EXTENDED-INTERVAL DOSING (“ONCE-DAILY”) -This approach exploits the concentration-dependent killing and post-antibiotic effect of aminoglycosides, and is generally as efficacious as traditional dosing with possibly less toxicity. However, this strategy has not been adequately studied in all populations. Inclusion criteria: -Patients with suspected or documented Gram-negative infections Exclusion criteria: -Creatinine clearance <60 ml/min -Abnormal body composition (e.g. morbid obesity, burns) -Meningitis, endocarditis, or osteomyelitis Dosing: CrCl >60 ml/min Dose (gentamicin, tobramycin) 5 mg/kg/dose IV q24h Monitoring: ·Patients anticipated to receive aminoglycosides for >7 days should have levels monitored. ·For patients who require monitoring, draw a single trough level. Peak levels are not useful. ·Trough level should be drawn <30 minutes before next dose. It is not necessary to wait until before the third dose to draw this level. Desired level (gentamicin, tobramycin) Trough <1 mcg/ml (<0.3 mcg/ml optimal) GRAM-POSITIVE COMBINATION DOSING (“SYNERGY”) -Patients with serious Gram-positive infections may receive aminoglycosides in combination to achieve synergistic killing. Inclusion criteria: -Patients with serious Gram-positive infection (e.g. endocarditis) being treated with a -lactam or vancomycin. Exclusion criteria -Patients with documented serious Gram-negative infections (e.g. Pseudomonas) receiving aminoglycosides in combination with a beta-lactam agent. (see above) Dosing: CrCl Dose (gentamicin) >60 ml/min 1 mg/kg/dose IV q8h ·Contact pharmacy for maintenance doses for patients with CrCl <60 ml/min. Monitoring: ·Patients anticipated to receive aminoglycosides for ≥7 days should have levels monitored. ·For patients who require monitoring, draw peak and trough level. ·Peak levels should be drawn 30 minutes after the end of the infusion. Trough levels should be drawn immediately before the next dose. Levels should be drawn around the 3rd or 4th dose to allow the drug to reach steady-state. Desired level (gentamicin) Trough ≤1 mcg/ml Peak 3 mcg/ml 38 c. Standard Dosing and Adjustment in Renal Impairment (see previous section for dialysis dosing) CrCl (mL/min) = (140-Age) x Wt (kg)/ 72 x SCr (mg/dl) [for females multiply result by 0.85] Acyclovir-Caspofungin Drug CrCl >50 mL/min Acyclovir Herpes simplex infections 5 mg/kg/dose IV Q8h Amoxicillin Amphotericin B Amphotericin B Lipid Preps CrCl 10 - 50 mL/min CrCl <10 mL/min (ESRD not on HD) 5 mg/kg/dose IV Q12 - 24h 2.5 mg/kg IV Q24h HSV encephalitis/ Herpes zoster 10 mg/kg/dose IV Q8h 10 mg/kg/dose IV Q12 - 24h 5 mg/kg IV Q24h 500 mg po TID 250-500mg po BID 250-500mg po QD 0.3 - 1.0 mg/kg IV Q24h No Change No Change Dosage reductions in renal disease are not necessary. However, due to the nephrotoxic potential of the drug, reducing the dose or holding the drug in the setting of a rising serum creatinine may be warranted. Dose varies depending on indication. See Guidelines for Use. (ID approval required in most cases – see exceptions under Guidelines for Use) Ampicillin 1 - 2 g IV Q4 - 6h 1 - 1.5 g IV Q6h 1 g IV Q8 - 12h Cefazolin 1 - 2 g IV Q8h 1 - 2 g IV Q12h 0.5 - 1 g IV Q24h Caspofungin (ID approval required) LD=70 mg x1, then 50 mg Q24h No Change For hepatic dysfunction give 70mg IV x1 then 35mg IV daily. Patients on concomitant rifampin or phenytoin may require 70mg daily due to drug interactions. 39 Cefepime-Daptomycin Drug CrCl >50 mL/min CrCl 10 - 50 mL/min CrCl <10 mL/min (ESRD not on HD) Cefepime > 60 mL/min 1 - 2 g IV Q12h 30-60 mL/min 10-30 mL/min 1 - 2g IV 0.5 - 1 g IV Q24h Q24h 0.25 - 0.5 g IV Q24h Febrile Neutropenia, Meningitis 2g IV Q8h 1 - 2 g Q8h No Change No Change 0.75 - 1.5 g IV Q8h 0.75-1.5 g IV Q12-24h 0.5 g IV Q24h 400 mg IV Q12h 30-50 mL/min 10-30 mL/min No Change 200-400mg IV Q12h Meningitis 2g IV Q12h Endocarditis & Osteomyelitis: 2g IV q24h Cefuroxime 500 - 750 mg po Q12h 200 IV Q12h 250 mg po Q12h No Change 250-500mg po Q12h 400mg IV q8h 30-50 mL/min 10-30 mL/min No Change 400mg IV Q12h 750mg po Q12h No Change Clindamycin 0.25 - 0.5 g IV Q24h 0.5 g IV Q24h 1g IV Q24h The use of Q12h dosing intervals is recommended in ESRD due to the variability in halflife data observed in anephric patients. Pseudomonas infections 1g IV Q12h 1 - 2 g IV Q12 - 24h Ceftazidime Ceftriaxone Ciprofloxacin 1 - 2g IV Q12h 500mg po Q12h 200 IV Q12h 250 mg po Q12h 600 - 900 mg IV Q8h No Change 300-450mg po TID-QID No Change Daptomycin (ID approval required) Dosing varies by indication. 40 Ethambutol-Gentamicin Drug CrCl >50 mL/min CrCl 10 - 50 mL/min CrCl <10 mL/min (ESRD not on HD) Ethambutol 15 mg/kg po daily 7.5 - 10 mg/kg po daily 5 mg/kg po daily Fluconazole 100 - 400 mg po/IV Q24h 50 - 200 mg po/IV Q24h 50 - 100 mg po/IV Q24h Oral formulation is 100% bioavailable. IV use should be restricted to patients unable to take oral medications. Flucytosine (5FC) 12.5 - 37.5 mg/kg/dose po Q6h Steady-state serum 5-FC level measurements are difficult to obtain. However, they may be useful in guiding dosing of 5-FC in anuria. Bone marrow suppression has been associated with 2 hour post dose 5-FC peaks of >100 mg/L. Ganciclovir Gentamicin See Aminoglycoside Dosing & Monitoring section pg 37-38 With traditional dosing of gentamicin, peak (5-8 mg/L) and trough (<2mg/L) levels are recommended in patients anticipated to receive aminoglycosides for ≥7 days for severe Gram (-) infection. Lower doses (1 mg/kg/dose Q8h) are suggested when aminoglycosides are used synergistically in Gram (+) infections. Those patients with CRCl<60 mL/min, obesity, or increased fluid volume should be monitored with serum gentamicin levels. > 80mL/min 50-79mL/min 5mg/kg/dose 2.5mg/kg/dose IV Q12h IV Q12h ≥ 60 mL/min 5 mg/kg/dose IV Q24h The total daily dose of gentamicin can be administered as a single daily dose in patients with normal renal function (CrCl ³ 60 mL/min). Patients with decreased renal function or abnormal body composition should have their doses adjusted according to the recommendations adjacent 25-50 mL/min 10-25mL/min 12.5-37.5 12.5-37.5 mg/kg po mg/kg po Q12h Q24h 1.25 - 2.5 mg/kg IV Q12-24h 40-60 mL/min 1.2-1.5 mg/kg IV Q12h 20-40 mL/min 1.2-1.5 mg/kg IV Q12-24h 12.5 - 25 mg/kg po Q24h 1.25 mg/kg IV Q24h < 20 mL/min 2 mg/kg loading dose (Consult pharmacy for maintenance dose) 41 Imipenem-Quinupristin/dalfopristin Drug CrCl >50 mL/min CrCl 10 - 50 mL/min CrCl <10 mL/min (ESRD not on HD) Imipenem 500 mg IV Q6-8h max 50 mg/kg/day 500 mg IV Q8h < 20 mL/min 250-500 mg IV Q12h (or consider meropenem) Isoniazid 300 mg po daily No Change No Change 250 - 500 mg po/IV Q24h LD=500 mg x1, then 250 mg po/IV Q24h LD=500 mg x1, then 250 mg po/IV Q48h 750mg po/IV Q24h LD=750 mg x1, then 750 mg LD=750 mg x1, then 500 mg po/IV Q48h Levofloxacin Nosocomial pneumonia/ Pseudomonas infections Linezolid (ID po/IV Q48h 600mg po/IV BID No Change No Change approval required) Meropenem 0.5-1 g IV Q8h 25-50 mL/min 10-25 mL/min 0.5 - 1 g 0.5g IV Q12h IV Q12h 0.5 g IV Q24h Metronidazole 500 mg po/IV Q8h 500 mg po/IV Q8h 500 mg po/IV Q12h Adjustment for ESRD only for patients not receiving hemodialysis. Nafcillin 1 - 2 g IV Q4 - 6h No Change No Change Penicillin G 2 - 3 MU IV Q4 - 6h 1 - 2 MU IV Q4 - 6h 1 MU IV Q6h Piperacillin/ tazobactam (Zosyn) 3.375 - 4.5 g IV Q6 - 8h 3.375-4.5 g Q6-8h Pseudomonas infections Pyrazinamide Quinupristin/ dalfopristin (Synercid) (ID 2.25-3.375 g Q8h 4.5g Q6h for ClCr > 20 mL/min 20 - 25 mg/kg/day po No Change No Change Dose varies depending on indication. approval required) 42 Rifampin-Vancomycin Drug Rifampin Tobramycin TMP/SMX TMP/SMX is »90% bioavailable orally. When switching to oral therapy, consider that a single-strength tablet has 80mg of TMP, a doublestrength tablet 160mg of TMP. Voriconazole PO should be used when possible, as oral bioavailability >95%. May require dose adjustment in hepatic dysfunction. Consult ID pharmacy. Vancomycin For monitoring, see Vancomycin Monitoring section CrCl >50 mL/min CrCl 10 - 50 mL/min CrCl <10 mL/min (ESRD not on HD) 600 mg po daily No Change No Change See Gentamicin (above) and Aminoglycoside Dosing Section pg.37-38 Systemic GNR infections 10 mg TMP/kg/day IV divided Q6 - 12h 5 - 7.5 mg TMP/kg/day IV divided Q12 - 24h 2.5 - 5.0 mg TMP/kg IV Q24h Pneumocystis pneumonia 15 - 20 mg TMP/kg/day IV divided Q6 - 12h 10 - 15 mg TMP/kg/day IV divided Q12 - 24h 5 - 10 mg TMP/kg IV Q24h No Change No Change Oral dosing LD=400 mg po Q12h x 1 day, then 200 mg po Q12h IV dosing LD=6 mg/kg/dose IV Q12h x 2 doses, then 4mg/kg/dose IV Q12h The use of IV should be avoided in patients with CrCl<50 mL/min due to the accumulation of the intravenous vehicle and is contraindicated in ESRD. >60 mL/min 40-60 mL/min 20-40 mL/min 10 - 15 mg/kg 10 - 15mg/kg 5-10 mg/kg IV Q12h IV Q12 - 24h IV Q24 10-20mL/min 5-10 mg/kg IV Q24-48h <10 mL/min 10 - 15 mg/kg IV loading dose x1, redose according to serum levels (Consult ID pharmacy) 43 d.Dosage Adjustments in Hemodialysis Recommended doses are for critically ill patients with serious systemic infections. Lower doses may be used for less serious infections. Contact ID pharmacy for further assistance. CRRT: This assumes an ultrafiltration (UF) rate of 2L/h with continuous venous-venous hemofiltration [CVVH] and an UF rate of 1L/h and dialysate flow rate of 1L/h with continuous veno-venous hemodiafiltration [CVVHDF] and residual native GFR < 10 mL/min. DRUG Acyclovir CRRT HD Herpes simplex infections 2.5 – 5.0 mg/kg IV Q24h Herpes simplex infections 2.5 mg/kg IV Q24h & post HD HSV Encephalitis/ Herpes Zoster 5 – 7.5 mg/kg IV Q24h Ampicillin Ampicillin/ sulbactam (Unasyn®) Cefazolin Cefepime Cefotetan Ceftazidime Ciprofloxacin Fluconazole Ganciclovir Gentamicin 1 g IV Q 6h HSV Encephalitis/ Herpes Zoster 5 mg/kg IV Q24h & post HD 1 g IV Q 12h 1.5 g IV Q 6h 1.5 g IV Q 12h 1 g IV Q12h 2 g IV post HD only 2 g IV Q 12h 2 g IV post HD only 1 g IV Q 12h 2 g IV post HD only 2 g IV Q 12h 1 IV g post HD 400 mg IV Q 12h 400 mg po/IV Q 24 h 200 mg IV Q12 h or 250 mg PO q12h 200 mg po/IV post HD only 2.5-5.0 mg/kg IV Q24h 1.25 mg/kg IV post HD only Gram negative infections 2 mg/kg Loading Dose then 1.5 mg/kg IV Q 24 h Monitoring of serum levels is recommended; trough < 2mcg/mL Imipenem Levofloxacin Meropenem Penicillin G Piperacillin/ tazobactam (Zosyn®) Ticarcillin/ clavulanate (Timentin®) Tobramycin TMP/SMX Vancomycin Voriconazole Gram negative infections 2 mg/kg Loading Dose then 1 mg/kg IV post HD Monitoring of serum levels is recommended; trough < 2mcg/mL 500 mg IV Q 8h 250 mg IV Q 12h 500 mg Loading Dose then 250 mg po/IV Q24h 500 mg Loading Dose then 250 mg po/IV Q48h 1g IV Q12h 500 mg IV Q24h and post HD 2 MU IV Q 4-6h 1 MU IV Q6h 3.375 g IV Q6h or 4.5g Q 8h 2.25 g IV Q 8h 3.1 g IV Q8h 2 g IV Q12h Gram negative infections 2 mg/kg Loading Dose then 1.5 mg/kg IV Q 24 h Monitoring of serum levels is recommended; trough < 2mcg/mL 5 – 7.5 mg TMP/kg/day divided q12h – 24h 7.5 – 15 mg/kg IV Q24 Gram negative infections 2 mg/kg Loading Dose then 1 mg/kg IV post HD Monitoring of serum levels is recommended; trough < 2mcg/mL 2.5 – 5.0 mg TMP/kg Q24h Loading Dose 15 – 20 mg/kg then 500mg IV post HD only Monitoring of serum levels is Monitoring of serum levels is recommended; recommended; trough 10-15 mcg/mL trough 10-15 mcg/mL ORAL formulation should be administered when possible, as oral bioavailability >95%. The use of IV should be avoided in patients with CrCl<50 mL/min due to the accumulation of the IV vehicle (cyclodextran) and is contraindicated in ESRD. LD: 400 mg PO q12h x 2 doses only [>40 kg] MD: 200 mg PO q12h [<40 kg] 44 IV. Outpatient Abscess Guidelines General comments -No need for antibiotics for uncomplicated abscess drainage -High levels of MRSA (50-70% of S. aureus) -Low threshold for culture: with moderate to severe disease; antibiotic allergy; patient has received frequent antibiotics; not responding to initial therapy -Most abscesses are caused by S. aureus. However, group A streptococcus (S. pyogenes) is a concern with significant cellulitis and is not well covered by trimethoprim-sulfamethoxazole and may be resistant to doxycycline. -Ill patients may require initial admission and IV therapy Antibiotics Requiring Renal Dose Adjustment Drug CrCl > 50ml/min Cephalexin 500mg qid Trimethoprim2 DS tabs bid <50 kg: 1 DS tab tid sulfamethoxazole CrCl 10-50ml/min 500mg tid-bid 1 DS tab bid <50kg: 1 SS tab tid (Half of standard regimen) CrCl <10ml/min 250mg bid Avoid No culture available Oral regimens -Dicloxacillin 500 mg qid or cephalexin 500 mg qid, especially if group A streptococcus suspected -Antibiotics when MRSA suspected: -Trimethoprim-sulfamethoxazole 2 DS bid (<50 kg: 1 DS tid) -Doxycycline 100 mg bid -Clindamycin 300 mg tid -Low threshold for culture if complicated disease, allergy, or failure to respond MSSA -Dicloxacillin 500 mg qid -Cephalexin 500 mg qid -Penicillin allergy: review antibiotic sensitivities -Clindamycin 300 mg tid MRSA -Review antibiotic sensitivities -Trimethoprim-sulfamethoxazole 2 DS bid (< 50 kg: 1 DS tid) -Doxycycline 100 mg bid -Clindamycin 300 mg tid 45 V. Antibiotic Restrictions a. Antibiotic Restrictions at UCSF Medical Center Antibiotics listed below require approval of Infectious Diseases (ID) Pharmacy (415) 443-9421 Antibiotic Restriction AmBisome®(liposomal amphotericin) Caspofungin All initial usage requires the approval of the ID Pharmacist Cefepime Treatment for > 5 days restricted to patients with multi-drug resistant gram negative pathogens (MDRP) All initial usage requires the approval of the ID Pharmacist Ceftriaxone In the absence of MDRP, approval by infectious diseases is required for continuation of cefepime Treatment > 2grams/day restricted to endocarditis, osteomyelitis and meningitis Daptomycin All initial usage requires the approval of the ID Pharmacist Drotrecogin (Activated Protein C , Xigris®) Imipenem All usage requires approval by the ID Consult Service and ICU Team and ID Pharmacy Treatment for > 5 days restricted to patients with multi-drug resistant gram negative pathogens IV Fluconazole In the absence of MDRP, approval by infectious diseases is required for continuation of imipenem. Usage acceptable if patient is NPO Linezolid For the treatment of persons with systemic VRE infections or in patients intolerant of vancomycin. Meropenem All initial usage requires the approval of the ID Pharmacist Treatment for > 5 days restricted to patients with multi-drug resistant gram negative pathogens Synercid ® (Quinupristin/ dalfopristin) Vancomycin Voriconazole Combination therapy for gram-negative infection will be reserved for neutropenia or serious pseudomonal infection All antibacterials and antifungal continued for > 7 days will be reviewed for appropriateness In the absence of MDRP, approval by infectious diseases is required for continuation of meropenem All initial usage requires the approval of the ID Pharmacist Treatment for > 5 days restricted to patients with severe beta-lactam allergy with documented infection or d ocumented MRSA, MRSE, ampicillin-resistant enterococcus If continuation of vancomycin desired in the absence of a beta-lactam allergy or gram-positive infection, approval by infectious diseases required Use on Heme-Onc, Lung Transplant Service, Pediatric Heme-onc and Pediatric BMT, does not require approval when voriconazole used as monotherapy. All other services require approval. Injection: Only if patient is NPO. ALL combination (usually voriconazole with caspofungin) antifungal therapy requires approval Monotherapy shall be used in the treatment of presumed or documented gram-negative infection. In the absence of neutropenia or documented pseudomonal infection, 2-drug coverage will be narrowed to monotherapy in 3-5 days. If continuation of 2-drug coverage is desired and the patient is not neutropenic and/or with documented pseudomonal infection, continuation of combinations therapy requires approval by infectious diseases. In those instances in which the use of the given agent is deemed inappropriate, discussion will take place with the primary team to clarify indication. If continuation of therapy is deemed inappropriate and the primary service requests continuation of therapy, direct discussion between the primary team and the ID fellow or ID attending will be required for continuation of therapy The following combinations should not be used: -Clindamycin + metronidazole -Penicillin + cefazolin -Piperacillin/tazobactam + clindamycin or metronidazole (exception: Piperacillin/tazobactam + clindamycin can be used in the treatment of necrotizing fascitis) -Ampicillin/sulbactam + Metronidazole -Carbapenem + antipseudomonal beta-lactam 46 b. Antibiotic Restrictions at San Francisco General Hospital As of 5/7/04 – Requires the Approval of the Infectious Disease (ID) Fellow at (415) 719-4737 Antibiotic Restriction Amikacin Amphotericin B Cholesteryl Sulfate Complex Azithromycin Capreomycin Ceftriaxone Ciprofloxacin Clarithromycin Fluconazole Itraconazole Levofloxacin Linezolid Meropenem/ Imipenem Oseltamivir Rifampin Tobramycin Trimetrexate Treatment > 48 hours restricted to: Isolates resistant to both gentamicin and tobramycin All other indications for amikacin require the approval of the ID Fellow. All usage requires the approval of the ID Fellow. Packet: Single one (1) gram dose to be dispensed without refill for use in treating Chlamydia infections or repeated doses for MAC prophylaxis. Tablets (600mg po) are restricted to 1200mg/week MAC prophylaxis. Usage requires the approval of the ID Fellow. Treatment > 2grams/day requires the approval of the ID Fellow except after 8:00 PM, 1 dose is allowed. The 1gram vial of ceftriaxone is not restricted. IV ciprofloxacin requires the approval of the ID Fellow. Usage is restricted to: 1. Helicobacter pylori 2. Documented/prophylaxis for MAC All other indications require the approval of the ID Fellow. Injection: Requires the approval of the ID Fellow. Capsule restricted to: 1. Aspergillus 2. Histoplasmosis 3. Dermatologist Rx for eosinophilic folliculitis, bullous tinea or recalcitrant fungal infections. Solution requires approval of the ID Fellow. Injection: Requires the approval of the ID Fellow. Tablet (750mg dose only): Requires approval of the ID Fellow. Restricted prescribing between 8pm-8am. For the treatment of persons with systemic VRE infections. All usage requires the approval of the ID Fellow. All usage requires the approval of the ID Fellow. Restricted to inpatient use in the management of influenza B outbreaks. Injection: Requires the approval of the ID Fellow. Injection: Treatment for > 48 hours is restricted to: 1. Documented Pseudomonas aeruginosa infection 2. Isolates resistant to gentamicin 3. All other indications require the approval of the ID Fellow. Usage requires the approval of the ID Fellow. The following combinations should not be used: 1) Cefotetan + metronidazole 2) Ceftriaxone + clindamycin 3) Clindamycin + metronidazole 4) Doxycycline + levofloxacin 5) Penicillin + cefazolin 6) Ampicillin/sulbatam + metronidazole 7) Piperacillin/tazobactam + clindamycin or metronidazole or cefazolin Dosing recommendations: 1) Metronidazole q8 hours 2) Meropenem 500mg IV q8 hours 3) Clindamycin 600mg IV q8 hours; 900mg IV q8 hours acceptable for PID Automatic substitution by Pharmacy as approved by Pharmacy and Therapeutics Committee: 1) Piperacillin/tazobactam 3.375 gm q6h will be substituted with Piperacillin/tazobactam 4.5gm q8h 2) Metronidazole q6h will be substituted with Metronidazole q8h 47